MNKD Stock - MannKind Corporation
Unlock GoAI Insights for MNKD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $285.50M | $198.96M | $99.77M | $75.44M | $65.14M |
| Gross Profit | $208.90M | $136.19M | $42.27M | $36.59M | $40.50M |
| Gross Margin | 73.2% | 68.5% | 42.4% | 48.5% | 62.2% |
| Operating Income | $72.59M | $8.68M | $-64,110,000 | $-47,022,000 | $-47,913,000 |
| Net Income | $27.59M | $-11,938,000 | $-87,400,000 | $-80,926,000 | $-57,240,000 |
| Net Margin | 9.7% | -6.0% | -87.6% | -107.3% | -87.9% |
| EPS | $0.10 | $-0.04 | $-0.44 | $-0.37 | $-0.26 |
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Visit WebsiteEarnings History & Surprises
MNKDEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $-0.01 | — | — | — |
Q4 2025 | Nov 5, 2025 | $0.01 | $0.03 | +200.0% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $0.04 | $0.00 | -94.6% | ✗ MISS |
Q2 2025 | May 8, 2025 | $0.03 | $0.04 | +33.3% | ✓ BEAT |
Q1 2025 | Feb 26, 2025 | $0.03 | $0.03 | 0.0% | = MET |
Q4 2024 | Nov 7, 2024 | $0.06 | $0.04 | -33.3% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-0.03 | $0.05 | +249.9% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $0.03 | $0.04 | +53.8% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | — | $0.02 | — | — |
Q4 2023 | Nov 7, 2023 | $0.01 | $0.02 | +160.8% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-0.01 | $-0.02 | -47.4% | ✗ MISS |
Q2 2023 | May 9, 2023 | $-0.05 | $-0.04 | +20.0% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | $-0.06 | $-0.07 | -16.7% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.10 | $-0.06 | +40.0% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.09 | $-0.11 | -22.2% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-0.10 | $-0.10 | 0.0% | = MET |
Q1 2022 | Feb 24, 2022 | $-0.06 | $-0.11 | -83.3% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.05 | $-0.04 | +20.0% | ✓ BEAT |
Q3 2021 | Aug 11, 2021 | $-0.04 | $-0.05 | -25.0% | ✗ MISS |
Latest News
Frequently Asked Questions about MNKD
What is MNKD's current stock price?
What is the analyst price target for MNKD?
What sector is MannKind Corporation in?
What is MNKD's market cap?
Does MNKD pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to MNKD for comparison